Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven - MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Managing Other Illnesses During illnesses like fever or infections, children with epilepsy may have an increased risk of seizures. Ensure adequate hydration, monitor fever, and follow your doctor’s ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

Individuals who had childhood epilepsy have an increased accumulation of brain amyloid later in life, potentially ...

Researchers at the University of Virginia Brain Institute and UVA School of Medicine will conduct a trial to see if the ...

Maternal psychologic distress between the first and second halves of pregnancy is associated with epilepsy in children aged 1 to 3.

Melissa Russell tells PEOPLE that while daughter Leah's peers are going off to college and starting their own lives, she ...

WWE Superstars have the most extravagant entrances in all of pro wrestling. Officials spare no expense when it comes to the ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

A 30-year-old man was treated for drug-resistant epilepsy through a procedure called temporal labectomy with amygdalo-hippocampectomy by doctors at Meenakshi Super Specialty Hospital.